Vaccine Adverse Event Reporting System

From WikiMD's WELLNESSPEDIA

Vaccine Adverse Event Reporting System (VAERS) is a United States national system for monitoring the safety of vaccines. It is co-managed by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). VAERS collects and analyzes data from reports of adverse events (possible side effects) that occur after the administration of US-licensed vaccines.

History[edit]

VAERS was established in 1990 as a national early warning system to detect possible safety concerns in U.S.-licensed vaccines. The program, which is a component of the CDC's Immunization Safety Office, was created in response to the National Childhood Vaccine Injury Act (NCVIA) of 1986.

Function[edit]

VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as "safety signals." If a safety signal is found in VAERS, further studies can be done in safety databases managed by the CDC, FDA, and other large linked databases.

Reporting[edit]

Healthcare providers are required to report certain adverse events and vaccine manufacturers are required to report all adverse events that come to their attention. VAERS is a passive reporting system, meaning it relies on individuals to send in reports of their experiences. Anyone can submit a report to VAERS, including parents, patients, and healthcare providers.

Limitations[edit]

While VAERS is a valuable tool for monitoring vaccine safety, it has limitations. The data VAERS collects is not enough to determine if a vaccine caused an adverse event. Most reports to VAERS are voluntary, which means they are subject to biases. This creates specific limitations on how the data can be used scientifically. Data from VAERS reports should always be interpreted with these limitations in mind.

See also[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.